Journal
FUTURE ONCOLOGY
Volume 13, Issue 8, Pages 705-714Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2016-0414
Keywords
biomarkers; bladder; GATA3; sarcomatoid urothelial carcinoma; TERT promoter mutation; upper urinary tract; ureter
Categories
Ask authors/readers for more resources
Aim: To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma. Methods & results: TERT C228T mutations were found in six of 17 cases (35%). p53 was expressed in 77% of these tumors. PAX8, GATA3, p40 and uroplakin III are less frequently expressed. Lymph node metastases were present in ten cases (59%). Eight patients (47%), including all three patients with TERT mutation, died of cancer within 2 years after surgery. Conclusion: Sarcomatoid carcinoma of the upper urinary tract is an aggressive tumor and the presence of TERT mutation may portend poor prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available